Welcome to our dedicated page for Merus news (Ticker: MRUS), a resource for investors and traders seeking the latest updates and insights on Merus stock.
Merus N.V. (MRUS) generates frequent news as an oncology company focused on full-length human bispecific and trispecific antibody therapeutics, known as Multiclonics®. Its disclosures highlight clinical progress, regulatory designations, corporate transactions and collaboration updates that are relevant to investors and observers of the biotechnology sector.
A central theme in recent Merus news is the development of petosemtamab (MCLA-158), a Biclonics® antibody targeting EGFR and LGR5. Company announcements describe interim data from phase 2 trials in metastatic colorectal cancer, including combinations with FOLFOX and FOLFIRI and monotherapy in later-line settings, as well as data in recurrent or metastatic head and neck squamous cell carcinoma. News releases detail response rates, safety observations and presentations at major scientific meetings such as the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the American Society of Clinical Oncology Annual Meeting.
Another important news stream concerns regulatory and strategic milestones. Merus has reported that the U.S. FDA granted Breakthrough Therapy Designation to petosemtamab in two head and neck cancer settings, and it has provided updates on phase 3 registration trials in first-line and later-line recurrent or metastatic HNSCC. In parallel, the company issues regular financial and business updates, including quarterly results, capital raises, and details on research collaborations with partners such as Incyte, Eli Lilly, Gilead, Ono and Biohaven.
Recent company announcements also cover the agreed acquisition of Merus by Genmab A/S through a cash tender offer and subsequent back-end transactions. Joint releases and 8-K filings describe the tender offer terms, acceptance levels, change of control and plans for a subsequent offering period. For users following MRUS news, this page offers a consolidated view of clinical, regulatory, financial and corporate developments, including the transition of Merus into an indirect wholly owned subsidiary of Genmab.
Merus N.V. (Nasdaq: MRUS) announced the pricing of a public offering of 3,859,650 common shares at $28.50 per share, generating approximately $110.0 million in gross proceeds. The offering, set to close on or about November 9, 2021, includes an option for underwriters to purchase an additional 578,947 shares. The funds will be utilized for advancing clinical development, preclinical research, and general corporate purposes. Jefferies LLC and SVB Leerink LLC are the joint book-running managers for the offering.
Merus N.V. (Nasdaq: MRUS) has announced a proposed underwritten public offering of its common shares to advance its clinical development of innovative bispecific and trispecific antibodies. The offering includes an additional 30-day option for underwriters to purchase 15% more shares. Proceeds will fund clinical and preclinical research, technology development, and working capital. Jefferies LLC and SVB Leerink LLC are the joint managers for this offering, which is contingent on market conditions. The offering follows a previously filed shelf registration statement with the SEC.
Merus N.V. (Nasdaq: MRUS) announced positive developments regarding its zenocutuzumab (Zeno) program after a Type B meeting with the FDA, securing alignment on a potential tumor-agnostic indication. The company shared interim clinical results for its MCLA-158 program at the AACR-NCI-EORTC Conference, with three of seven advanced head and neck cancer patients showing partial responses. Financially, the company reported collaboration revenue of $13.7 million for Q3 2021, up from $8.6 million a year prior, although operating expenses rose significantly. Cash reserves are projected to fund operations into H2 2024.
Merus, a clinical-stage oncology company, presented promising clinical data for its MCLA-158 treatment for advanced head and neck squamous cell carcinoma (HNSCC) during the AACR-NCI-EORTC conference. Out of 10 patients, 3 achieved partial responses and 1 a complete response. In preclinical studies, the Zeno antibody demonstrated a potent ability to block cancer cell growth. The safety profile for MCLA-158 showed infusion reactions as the most common adverse event. Future updates on the MCLA-158 trial are planned for 2022, indicating potential for further therapeutic advancements.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced two poster presentations scheduled for the AACR-NCI-EORTC Virtual Conference on Molecular Targets and Cancer Therapeutics from October 7-10, 2021. The presentations focus on:
- Zenocutuzumab: Targeting HER2/HER3 in cancers with NRG1 fusions.
- MCLA-158: Evaluating antitumor activity in advanced head and neck squamous cell carcinoma.
The posters will be available on demand throughout the conference and on the company's website.
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced CEO Bill Lundberg's participation in several upcoming investor conferences. Key events include a panel discussion at Citi’s 16th Annual BioPharma Virtual Conference on September 9, 2021, a pre-recorded presentation at H.C. Wainwright 23rd Annual Global Investment Conference available on September 13, and a presentation at the 2021 Cantor Virtual Global Healthcare on September 27, 2021. The webcasts will be accessible on the company's investor page, with archived presentations available for a limited time.
Merus N.V. (Nasdaq: MRUS) reported its Q2 2021 financial results, with cash and equivalents rising to $352.8 million, expected to fund operations into H2 2024. Collaboration revenue surged to $12.4 million, primarily from Eli Lilly and Incyte. The company shared promising interim results from its Zeno program targeting NRG1 fusion cancers, showing 42% partial response in pancreatic cancer. Ongoing trials for MCLA-158 and MCLA-145 are set for updates in Q4 2021. However, R&D expenses increased, leading to a net loss of $27.4 million for the quarter.
Merus N.V. (Nasdaq: MRUS) announced the novel mechanism of action for its clinical-stage Biclonics® T-cell agonist, MCLA-145, which targets PD-L1 and CD137. Published in Nature Communications, the study reveals MCLA-145's ability to activate immune T cells in tumor microenvironments while blocking inhibitory signals. Currently, MCLA-145 is in a phase 1 multicenter dose escalation study for solid tumors, with Merus retaining U.S. commercialization rights, while Incyte holds rights outside the U.S.
On July 7, 2021, Merus N.V. (Nasdaq: MRUS) announced that CEO Bill Lundberg, M.D. will participate in the panel discussion titled Moving Beyond Monoclonals: The Potential of Multispecific Therapies at William Blair's Biotech Focus Conference 2021. The event is scheduled for July 14 at 11:20 a.m. ET. Investors can access the live webcast on the Company's website, with an archived presentation available for a limited time.
Merus specializes in developing innovative multispecific antibodies, known as Biclonics® and Triclonics®.
Merus has shared interim efficacy data from the phase 1/2 eNRGy trial for zenocutuzumab (Zeno) in patients with NRG1+ cancers, with 61 patients enrolled as of April 13, 2021. Notable findings reveal a 42% overall response rate in pancreatic cancer and a 29% rate across various NRG1+ tumor types. Zeno demonstrates a favorable safety profile, with most adverse events being mild or moderate. The company plans to discuss these results further in an investor call on June 6, 2021.